CA2506476A1 - Method of treatment of myocardial infarction - Google Patents
Method of treatment of myocardial infarction Download PDFInfo
- Publication number
- CA2506476A1 CA2506476A1 CA002506476A CA2506476A CA2506476A1 CA 2506476 A1 CA2506476 A1 CA 2506476A1 CA 002506476 A CA002506476 A CA 002506476A CA 2506476 A CA2506476 A CA 2506476A CA 2506476 A1 CA2506476 A1 CA 2506476A1
- Authority
- CA
- Canada
- Prior art keywords
- tyrosine kinase
- kinase inhibitor
- src family
- family tyrosine
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Abstract
Myocardial infarction in a mammal is treated by administering to the mammal a therapeutically effective amount of a chemical Src family tyrosine kinase protein inhibitor and the use of such inhibitor compounds for the preparation of a medicament for treating myocardial infarction. Myocardial infarction can be prevented by administering to the mammal a prophylactic amount of the inhibitor. The inhibitor preferably is an inhibitor of Src protein selected from the group consisting of a pyrazolopyrimidine class Src family tyrosine kinase inhibitor, a macrocyclic dienone class Src family tyrosine kinase inhibitor, a pyrido[2,3-d]pyrimidine class Src family tyrosine kinase inhibitor, a 4-anilino-3-quinolinecarbonitrile class Src family tyrosine kinase inhibitor, and a mixture thereof. The Src family tyrosine kinase inhibitors can be used to prepare medicaments for the treatment of myocardial infarction. Also disclosed are articles of manufacture containing a chemical Src family tyrosine kinase inhibitor.
Claims (33)
1. A method for treating a mammal suffering from a myocardial infarction comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising a chemical Src family tyrosine kinase inhibitor.
2. The method of claim 1 wherein the mammal is a human.
3. The method of claim 1 wherein the mammal is a non-human mammal.
4. The method of claim 1 wherein the Src family tyrosine kinase inhibitor is a an inhibitor of Src protein.
5. The method of claim 4 wherein the chemical inhibitor is selected from the group consisting of a pyrazolopyrimidine class Src family tyrosine kinase inhibitor, a macrocyclic dienone class Src family tyrosine kinase inhibitor, a pyrido[2,3-d]pyrimidine class Src family tyrosine kinase inhibitor, a 4-anilino-3-quinolinecarbonitrile class Src family tyrosine kinase inhibitor, and a mixture thereof.
6. The method of claim 5 wherein the pyrazolopyrimidine class Src family tyrosine kinase inhibitor is a member of the group consisting of 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d-] pyrimidine, 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d-]pyrimidine, and a mixture thereof.
7. The method of claim 5 wherein the macrocyclic dienone class Src family tyrosine kinase inhibitor is a member of the group consisting of Geldanamycin, Herbimycin A, Radicicol 82146, and a mixture thereof.
8 The method of claim 5 wherein the pyrido[2,3-d]pyrimidine class Src family tyrosine kinase inhibitor is PD173955.
9. The method of claim 5 wherein the 4-anilino-3-quinolinecarbonitrile class Src family tyrosine kinase inhibitor is SKI-606.
10. The method of claim 1 wherein the pharmaceutical composition is administered to the mammal by intraperitoneal injection.
11. The method of claim 1 wherein the pharmaceutical composition is administered to the mammal by intravenous injection.
12. The method of claim 1 wherein the pharmaceutical composition is administered to the mammal within about 6 hours after the myocardial infarction.
13. The method of claim 1 wherein the pharmaceutical composition is administered to the mammal within about 24 hours after the myocardial infarction.
14. An article of manufacture comprising packaging material and a pharmaceutical composition contained within the packaging material, wherein the pharmaceutical composition is present in an amount capable of reducing necrosis in coronary tissue suffering from an impeded blood supply, the packaging material comprising a label which indicates that said pharmaceutical composition can be used fox treatment of myocardial infarction, and wherein the pharmaceutical composition comprises a chemical Src family tyrosine kinase inhibitor and a pharmaceutically acceptable carrier therefor.
15. The article of manufacture of claim 14 wherein the Src family tyrosine kinase inhibitor is an inhibitor of Src protein.
16. The article of manufacture of claim 15 wherein the chemical inhibitor is selected from the group consisting of a pyrazolopyrimidine class Src family tyrosine kinase inhibitor, a macrocyclic dienone class Src family tyrosine kinase inhibitor, a pyrido[2,3-d]pyrimidine class Src family tyrosine kinase inhibitor, a 4-anilino-3-quinolinecarbonitrile class Src family tyrosine kinase inhibitor, and a mixture thereof.
17. The article of manufacture of claim 16 wherein the pyrazolopyrimidine class Src family tyrosine kinase inhibitor is selected from the group consisting of 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d-]
pyrimidine, 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d-]pyrimidine, and a mixture thereof.
pyrimidine, 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d-]pyrimidine, and a mixture thereof.
18. The article of manufacture of claim 15 wherein the macrocyclic dienone class Src family tyrosine kinase inhibitor is selected from the group consisting of Geldanamycin, Herbimycin A, Radicicol R2146, and a mixture thereof.
19. The article of manufacture of claim 15 wherein the pyrido[2,3-d]pyrimidine class Src family tyrosine kinase inhibitor is PD173955.
20. The article of manufacture of claim 15 wherein the 4-anilino-3-quinolinecarbonitrile class Src family tyrosine kinase inhibitor is SKI-606.
21. A method for prophylactic treatment of a mammal at risk of myocardial infarction, the method comprising administering to the mammal a prophylactic amount of a pharmaceutical composition comprising a chemical Src family tyrosine kinase inhibitor.
22. The method of claim 21 wherein the mammal is a non-human mammal.
23. The method of claim 21 wherein the mammal is a human.
24. The method of claim 21 wherein the pharmaceutical composition is orally administered to the mammal.
25. The method of claim 21 wherein the pharmaceutical composition is parenterally administered to the mammal.
26. The method of claim 21 wherein the Src family tyrosine kinase inhibitor is a pyrazolopyrimidine class Src family tyrosine kinase inhibitor.
27. The method of claim 26 wherein the pyrazolopyrimidine class Src family tyrosine kinase inhibitor is selected from the group consisting of 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d-] pyrimidine, 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d-] pyrimidine, and a mixture thereof.
28. The method of claim 21 wherein the Src family tyrosine kinase inhibitor is a 4-anilino-3-quinolinecarbonitrile compound.
29. The use of a chemical Src family tyrosine kinase inhibitor for the manufacture of a medicament for the treatment of myocardial infarction.
30. The use according to claim 29 wherein the chemical Src family tyrosine kinase inhibitor is selected from the group consisting of a pyrazolopyrimidine class Src family tyrosine kinase inhibitor, a macrocyclic dienone class Src family tyrosine kinase inhibitor, a pyrido[2,3-d]pyrimidine class Src family tyrosine kinase inhibitor, a 4-anilino-3-quinolinecarbonitrile class Src family tyrosine kinase inhibitor, and a mixture thereof.
31. The use according to claim 30 wherein the pyrazolopyrimidine class Src family tyrosine kinase inhibitor is selected from the group consisting of 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d-] pyrimidine, 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d-]pyrimidine, and a mixture thereof.
32. The use according to claim 30 wherein the macrocyclic dienone class Src family tyrosine kinase inhibitor is selected from the group consisting of Geldanamycin, Herbimycin A, Radicicol 82146, and a mixture thereof.
33. The use according to claim 30 wherein the 4-anilino-3-quinolinecarbonitrile class Src family tyrosine kinase inhibitor is SKI-606.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/298,377 US20030130209A1 (en) | 1999-12-22 | 2002-11-18 | Method of treatment of myocardial infarction |
| US10/298,377 | 2002-11-18 | ||
| PCT/US2003/037653 WO2004045563A2 (en) | 2002-11-18 | 2003-11-18 | Method of treatment of myocardial infarction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2506476A1 true CA2506476A1 (en) | 2004-06-03 |
| CA2506476C CA2506476C (en) | 2011-09-27 |
Family
ID=32324361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2506476A Expired - Fee Related CA2506476C (en) | 2002-11-18 | 2003-11-18 | Method of treatment of myocardial infarction |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20030130209A1 (en) |
| EP (1) | EP1567160A4 (en) |
| JP (1) | JP2006510620A (en) |
| KR (1) | KR101174333B1 (en) |
| CN (1) | CN100577170C (en) |
| AU (1) | AU2003293037A1 (en) |
| BR (1) | BR0316382A (en) |
| CA (1) | CA2506476C (en) |
| MX (1) | MXPA05005307A (en) |
| PL (1) | PL209912B1 (en) |
| RU (1) | RU2330665C2 (en) |
| WO (1) | WO2004045563A2 (en) |
| ZA (1) | ZA200504774B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2041071E (en) | 2006-06-29 | 2014-09-23 | Kinex Pharmaceuticals Llc | Biaryl compositions and methods for modulating a kinase cascade |
| TWI457336B (en) | 2006-12-28 | 2014-10-21 | Kinex Pharmaceuticals Llc | Composition and methods for modulating a kinase cascade |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| WO2009051848A1 (en) | 2007-10-20 | 2009-04-23 | Kinex Pharmaceuticals, Llc | Pharmaceutical compositions for modulating a kinase cascade and methods of use thereof |
| WO2009142679A2 (en) * | 2008-03-26 | 2009-11-26 | Orthologic Corp. | Methods for treating acute myocardial infarction |
| EP2905024A1 (en) * | 2014-02-07 | 2015-08-12 | Institut Quimic De Sarriá Cets, Fundació Privada | Pyrido[2,3-d]pyrimidine-7(8H)-one derivatives for the treatment of infections caused by Flaviviridae |
| EP3569249A4 (en) * | 2016-12-27 | 2020-11-11 | Osaka University | Medicinal composition for treating intractable heart disease |
| CN113209096B (en) * | 2021-05-17 | 2022-06-14 | 武汉大学 | Application of Pexidantinib in preparation of medicines for preventing, relieving and/or treating myocardial infarction and related diseases thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731343A (en) * | 1995-02-24 | 1998-03-24 | The Scripps Research Institute | Method of use of radicicol for treatment of immunopathological disorders |
| US5593997A (en) * | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
| AU4753697A (en) | 1996-10-01 | 1998-04-24 | South Alabama Medical Science Foundation | Method for diminishing myocardial infarction using protein phosphatase inhibitors |
| US7863444B2 (en) * | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
| US6235740B1 (en) * | 1997-08-25 | 2001-05-22 | Bristol-Myers Squibb Co. | Imidazoquinoxaline protein tyrosine kinase inhibitors |
| IL135176A0 (en) * | 1997-11-10 | 2001-05-20 | Bristol Myers Squibb Co | Benzothiazole derivatives and pharmaceutical compositions containing the same |
| DE69943374D1 (en) * | 1998-05-29 | 2011-06-01 | Us Government | PROCESS FOR MODULATING THE ANGIOGENESIS BY TYROSINE KINASE SRC |
| TR200101395T2 (en) * | 1998-09-18 | 2001-11-21 | Basf Ag. | 4-Aminopyrrolopyrimidines as kinase inhibitors |
| US6921763B2 (en) * | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| EP1250155B1 (en) | 1999-12-22 | 2008-04-16 | The Scripps Research Institute | Angiogenesis and vascular permeability modulators and inhibitors |
| US6521618B2 (en) | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| SE518028C2 (en) | 2000-04-17 | 2002-08-20 | Ericsson Telefon Ab L M | Method and method of avoiding congestion in a macro diversity cellular radio system |
| JP2005500261A (en) * | 2001-04-10 | 2005-01-06 | バーテックス ファーマシューティカルズ インコーポレイテッド | Isoxazole derivatives as inhibitors of Src and other protein kinases |
| IL159735A0 (en) * | 2001-07-09 | 2004-06-20 | Aventis Pharma Inc | Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity |
| US20060167021A1 (en) * | 2002-10-04 | 2006-07-27 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Inhibition of src for treatment of reperfusion injury related to revascularization |
-
2002
- 2002-11-18 US US10/298,377 patent/US20030130209A1/en not_active Abandoned
-
2003
- 2003-11-18 CA CA2506476A patent/CA2506476C/en not_active Expired - Fee Related
- 2003-11-18 RU RU2005119174/14A patent/RU2330665C2/en not_active IP Right Cessation
- 2003-11-18 PL PL377040A patent/PL209912B1/en unknown
- 2003-11-18 AU AU2003293037A patent/AU2003293037A1/en not_active Abandoned
- 2003-11-18 JP JP2004554028A patent/JP2006510620A/en active Pending
- 2003-11-18 WO PCT/US2003/037653 patent/WO2004045563A2/en active Application Filing
- 2003-11-18 BR BR0316382-2A patent/BR0316382A/en not_active IP Right Cessation
- 2003-11-18 MX MXPA05005307A patent/MXPA05005307A/en active IP Right Grant
- 2003-11-18 CN CN200380108930A patent/CN100577170C/en not_active Expired - Fee Related
- 2003-11-18 KR KR1020057008850A patent/KR101174333B1/en not_active IP Right Cessation
- 2003-11-18 EP EP03790028A patent/EP1567160A4/en not_active Withdrawn
-
2005
- 2005-06-10 ZA ZA2005/04774A patent/ZA200504774B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050086698A (en) | 2005-08-30 |
| AU2003293037A1 (en) | 2004-06-15 |
| BR0316382A (en) | 2005-10-04 |
| JP2006510620A (en) | 2006-03-30 |
| CN100577170C (en) | 2010-01-06 |
| KR101174333B1 (en) | 2012-08-16 |
| CN1738624A (en) | 2006-02-22 |
| CA2506476C (en) | 2011-09-27 |
| EP1567160A2 (en) | 2005-08-31 |
| WO2004045563A3 (en) | 2004-12-23 |
| WO2004045563A2 (en) | 2004-06-03 |
| PL209912B1 (en) | 2011-11-30 |
| MXPA05005307A (en) | 2005-08-16 |
| US20030130209A1 (en) | 2003-07-10 |
| EP1567160A4 (en) | 2009-06-10 |
| RU2005119174A (en) | 2006-01-20 |
| PL377040A1 (en) | 2006-01-23 |
| RU2330665C2 (en) | 2008-08-10 |
| ZA200504774B (en) | 2006-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2004200573B2 (en) | Method of Treating Nitrate-induced Tolerance | |
| WO2005089366A3 (en) | Method of treatment of myocardial infarction | |
| RU2002129508A (en) | COMBINED PRODUCT INCLUDING NESTEROID ANTIANDROGEN AND EGFR-TYROZINKINASE INHIBITOR | |
| JP2007169278A (en) | Medicinal combination for luts treatment | |
| MX2014000029A (en) | Heteroaryl-substituted pyrazolopyridines and use thereof as soluble guanylate cyclase stimulators. | |
| WO2002066477A3 (en) | Imidazopyridines | |
| AU2002337105B2 (en) | Combination of a NSAID and a PDE-4 inhibitor | |
| CN108430510B (en) | Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with inhibitors of neutral endopeptidase (NEP inhibitors) and/or angiotensin AII antagonists and uses thereof | |
| EP1460077B1 (en) | Novel pyrazolopyrimidones and their use as PDE inhibitors | |
| US20190275046A1 (en) | Novel combination | |
| EP2363130A1 (en) | Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases | |
| US20060241089A1 (en) | Dipyridamole, acetylsalicylic acid, and angiotensin II antagonist pharmaceutical compositions | |
| CA2506476A1 (en) | Method of treatment of myocardial infarction | |
| KR20220101122A (en) | Combination of BTK inhibitor and MDM2 inhibitor for the treatment of cancer | |
| JP2009520806A (en) | Pharmaceutical combination of PDE-5 inhibitor and 5-α reductase inhibitor | |
| TW200407153A (en) | Novel combination | |
| JP2006520777A (en) | Treatment of type 1 diabetes with PDE5 inhibitors | |
| MX2010012540A (en) | Imidazo [2,1-b] quinazolin-2-one derivatives and their use as platelet anti-aggregative agents. | |
| US4559326A (en) | Antiinflammatory compositions and methods | |
| CA1273875A (en) | Antiinflammatory compositions and methods | |
| EE200200695A (en) | (-) - 5- (3-Chlorophenyl) -alpha- (4-chlorophenyl) -alpha- (1-methyl-1H-imidazol-5-yl) tetrazolo [1,5-a] quinazoline-7-methanamine, a process for its preparation and use, a pharmaceutical composition and a method for its preparation | |
| WO2004085436A3 (en) | Pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents | |
| CN1662257A (en) | Combination of PDE5 inhibitors with angiotensin II receptor antagonists | |
| US20030004168A1 (en) | Product comprising a heterotrimeric g protein signal transduction inhibitor associated with anti-hypertensive agent for therapeutic use in the treatment of arterial hypertension | |
| CA2590224A1 (en) | Method for reduction, stabilization and prevention of rupture of lipid rich plaque |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20171120 |